Current biopharma R&D costs ‘unsustainable’, warns report

20th June 2017 Uncategorised 0

Improving return on investment in R&D is “imperative” to the future success of global pharma and biotech companies, warns a new report by Ernst & Young.

More: Current biopharma R&D costs ‘unsustainable’, warns report
Source: News